AbCellera Biologics Inc.
NASDAQ: ABCL0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- NASDAQ Global Select
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Carl Hansen
- Employees
- 596
- Headquarters
- Vancouver, Canada
- IPO year
- 2020
- Market cap
- $1.8B
- Website
- https://www.abcellera.com
Loading ABCL…
Loading profile data…Frequently asked questions about ABCL
What does AbCellera Biologics Inc. (ABCL) do?
AbCellera Biologics Inc. specializes in pioneering an advanced platform for the discovery of antibodies. This comprehensive, AI-driven system meticulously explores and analyzes natural immune systems to identify antibodies suitable for the creation of new pharmaceutical drugs. As of December 31, 2021, the company had cultivated 156 discovery pro...
Where does ABCL trade?
AbCellera Biologics Inc. (ABCL) trades on the NASDAQ Global Select.
What sector is ABCL in?
AbCellera Biologics Inc. (ABCL) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of AbCellera Biologics Inc.?
Carl Hansen is the chief executive officer of AbCellera Biologics Inc. (ABCL).
Where is AbCellera Biologics Inc. headquartered?
AbCellera Biologics Inc. is headquartered in Canada.
Does ABCL pay a dividend?
AbCellera Biologics Inc. (ABCL) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did ABCL go public?
AbCellera Biologics Inc. (ABCL) completed its initial public offering in 2020.